Countdown up to congress

   Romanian               English
    Romanian             English
ARSF Congress 2016
ARSF Congress 2016 - Program
ARSF Congress 2016 - History
ARSF Congress 2016 - Poster
ARSF Congress 2016 - Contact

Congress program

Thursday, October 6, 2016

8.30 - 9.00: Opening Ceremony In Memoriam Prof. Dr. Mihai Voiculescu
09.00 - 10.40 Session 1 - HBV infection
Chairmens: Patrick Marcellin, George Papatheodoridis, Geoffrey Dusheiko

09.00 - 09.20 Geoffrey Dusheiko An update of HBV infection
09.20 - 09.40 G. Papatheodoridis Nucleos(t)ide analogues withdrawal:
in whom, when and why ?
09.40 - 10.00 Laurentiu Micu Management of HBV infection in pregnancy
10.00 - 10.20 Patrick Marcellin Advantages of combination of PEG IFN + TDF versus monotherapy
10.20 - 10.40 Round table: Conclusions and recommendation

10.40 - 11.40 Symposium GILEAD

Coffee break

11.40 - 12.00 Symposium PROTON



12.00 - 13.30 Session 2 - HCV infection I
Chairmens: Peter Ferenci, Vlad Ratziu, Lawrence Serfaty

12.00 - 12.20 V.Ratziu HCV eradication benefits
12.20 - 12.40 K. Antonov
D. Jelev
What is happened with the liver disease after the
eradication of HCV infection?
12.40 - 13.00 L. Serfaty Retreating patients with DAA Failure
13.00 - 13.20 P. Ferenci Treatment of HCV - is the job done?
13.20 - 13.30 Round table: Conclusions

13.30 - 14.30 Simposium ABBVIE

14.30 - 15.30 Lunch Break

15.30 - 16.00 Patrizia Burra : The management of HCV infection post-transplantation

16.00 - 16.20 Mariana Mihaila: The management of HBV infection post-transplantation




16.20 - 18.15 Session 3 - HCV infection II
Chairmens: Anca Trifan, Oliviu Pascu, Laura Iliescu

16.20 - 16.40 Laura Iliescu Management of IFN-free therapy in patients with HCV liver cirrhosis and co-morbidities
16.40 - 17.00 Anca Trifan What happens after SVR in HCV patients with cirrhosis
17.00 - 17.20 Cristina Cijevschi, C. Mihai HCV infection and the risk of liver cancer in DAA era
17.20 - 17.40 Simona Ruta Who might still benefit from the interferon-based therapies
in chronic hepatitis C in 2016
17.40 - 18.00 Gabriela Oprisan Patterns of HCV mutations
18.00 - 18.15 Round table: Conclusions



Friday, October 7, 2016

08.30 - 10.00 Session 4 – Liver fibrosis
Chairmens: Dan Dumitrascu, Carol Stanciu, Manuela Neuman

8.30 - 8.50 O. Orasan, D. Dumitrascu Non-invasive evaluation of liver fibrosis
08.50 - 09.10 Carol Stanciu, Camelia Cojocariu The place and the importance of the liver biopsy in evaluation of liver fibrosis
09.10 - 09.30 Manuela Neuman NAFLD and moderate alcohol consumption
09.30 - 09.50 Azra Husic Selimovic Actual antifibrotic therapies in patients with chronic liver disease
09.50 - 10.10 I. Copaci Coagulation disorders in patients with advanced fibrosis/cirrhosis: the ups and downs
10.10 - 10.30 Round table: Conclusions

10.30 - 11.00 Coffee Break



11.00 - 12.40 Session 5 - NASH
Chairmens: Arun Sanyal, Vlad Ratziu, Carmen Fierbinteanu-Braticevici

11.00 - 11.20 Carmen
Fierbinteanu - Bratisevici
Who are the patients at risk of NAFLD/NASH
progression and complications ?
11.20 - 11.40 Arun Sanyal Emerging trends treatment of nonalcoholic steatohepatitis
11.40 - 12.00 R. Pais Risk of liver cancer in NASH
12.00 - 12.20 V. Ratziu Innovative new therapy in NASH
12.20 - 12.40 Round table: Conclusions

12.40 - 13.40 Simposium Alfa Wassermann

13.40 - 14.15 Simposium Merz

14.15 - 15.30 Lunch Break



15.30 - 18.00 Session 6 - Cirrhosis and its complications
Chairmens: Monica Acalovschi, Maxim Mallete

15.30 - 15.50 Monica Acalovschi Who needs HCC surveillance and how to do it
15.50 - 16.10 M. Munteanu Awareness of the severity of liver disease and access to interferon-free regimen treatment of chronic hepatitis C - a French tertiary center and Romanian experiences
16.10 - 16.30 M. Mallete New perspectives concerning the prevention of variceal bleeding
16.30 - 16.50 C. Achim
16.50 - 17.10 M. Toma Radiointerventional treatment of inoperable HCC
17.10 - 17.30 M. Grigorie Surgical treatment of HCC
17.30 - 17.50 E. Mindrut Current treatment strategies in HCC in 2016
17.50 - 18.00 Round table: Conclusions



Saturday, 8 October, 2016

09.00 - 10.40 Session 7 - Autoimmune liver diseases
Chairmens: Coman Tanasescu, Simona Valean, Manuela Neuman

09.00 - 09.10 Simona Valean Introduction
09.10 - 09.30 Anca Trifan, Ana Maria Sangeap Autoimmune hepatitis clinical presentation and diagnosis
09.30 - 09.50 Doinita Crisan Autoimmune hepatitis: histological aspects and their contribution to diagnosis
09.50 - 10.05 Coman Tanasescu Biological therapy of autoimmune hepatitis – between theory and practice
10.05-10.25 Manuela Neuman sRank1-inhibitor- induced autoimmune hepatitis
10.25 - 10.40 Round table: Conclusions

10.40 - 11.00 Coffee Break



11.00 - 13.00 Session 8 - Liver transplantation
Chairmens: Antonio Rampoldi, Irinel Popescu, Dana Tomescu

11.00 - 11.20 V. Zota, Carmen Pantis Management of marginal liver donors, a new challenge for transplantation medicine
11.20 - 11.40 Mariana Mihaila The liver transplant ABO incompatibility
11.40 - 12.00 Antonio Rampoldi Advanced application of TIPS: portal cavernoma; portal hypertension in OLT
12.00 - 12.20 Dana Tomescu Living related liver transplant for acute liver failure
12.20 - 12.40 Irinel Popescu Liver Transplant in Romania in 2016
12.40 - 13.00 Round table: Conclusions

13.00 Closing remarks



Dear colleagues,

It's a privilege for us to invite you to Romanian Association for the Study of Liver (RASL) annual meeting, which remains the premier liver meeting. We proudly celebrate this year the 26th Congress of RASL together with our friends from France (the 5th French-Romanian Symposium) and from Balkan (7th Postgraduate Balkan Hepatology Course).

The meeting is focusing on highly specialized topics in liver diseases. Attendees have the unique opportunity to meet the leader professors in the field of Hepatology. Moreover, young colleagues who share same interests, will have the opportunity to networking the with the faculty coming from Europe and North America . Our program is designed for all professionals involved with the study, treatment, and management of liver disease. It will feature a comprehensive review of evidence-based approaches to the diagnosis and management of a wide range of hepatic disorders. New changes and improvements have been introduced in 2015, that will allow us more time to present the curriculum developed by the scientific committee. Our flexible, interesting agenda is based on the news in Hepatology and attendees' requests. The program brings still unsolved questions:

- Viral hepatitis B (HBV) treatment is now considered indefinite. How we can better monitor patients and prevent long term complications of virus and treatment effects?

- There are many DAA available to eradicate hepatitis C virus (HCV). Which are the best current HCV treatment strategies. What to do with "cured" patients after the virus was eradicated?

- Liver cancer is one of the most frequent and lethal digestive cancer. Who needs liver cancer surveillance and how to do it? We need to optimize the management of liver cancer and to have standard of care for liver cancer. Targeted liver cancer therapy is now possible.

- Optimizing diagnosis and treatment of alcoholic and non-alcoholic liver disease is one of the most attractive topic today. What are the therapeutic interventions?

- We need to known the best practice in fibrosis evaluation and its clinical and therapeutic consequences. The non-invasive evaluation of fibrosis is one of the most important subjects in Liver Congress.

- There are new strategies that focus on stratifying risk and individualizing care for portal hypertension, managing hepatic encephalopathy and fluid overload in cirrhosis, possible therapeutics for patients with cirrhosis of the liver.

The practice of liver disease has matured rapidly, and innovations in science have had an enormous impact on the ability to diagnose and treat our patients. The major goal of this new curriculum is to offer an up-to-date on the management of patients with liver disease, while also providing insight into patho-physiologic concepts in the specific disease.

This is an ideal continuing education opportunity for practicing hepatologists, gastroenterologists, infection disease specialist and other practitioners wanting to augment their clinical knowledge. In addition, the course will appeal to researchers, trainees, nurses and pharmacologists who want to enhance their knowledge of liver diseases.

We anticipate that new elements of The Romanian-French Meeting and 7th Balkan Hepatology Course in 2016 will engage both practicing physicians, scientists and industry with ample programming choices. The organizers hope that at the end of the Congress and Postgraduate Course the participants will enhance not only their knowledge but how to practice more efficient.

Presidents of the Congress
Anca Trifan M.D.
Manuela Neuman M.D.
Monica Acalovschi M.D.
Stephanos Hadziyannis M.D.
Patrick Marcellin M.D.

Irinel Popescu
Irinel Popescu
Patrick Marcellin
Patrick Marcellin
Stephanos_Hadzyiannis
Stephanos Hadzyiannis
Andreea Radasan
Andreea Radasan
Azra Husic Selimovic
Azra Husic Selimovic
Carmen Fierbinteanu
Carmen Fierbinteanu
Carol Stanciu
Carol Stanciu
Bogdan Dorobantu
Bogdan Dorobantu
Didier Samuel
Didier Samuel
Mona Munteanu
Mona Munteanu
Peter Ferenci
Peter Ferenci
George Papatheodoridis
George Papatheodoridis
Monica Acalovschi
Monica Acalovschi
Zahary Krastev
Zahary Krastev
Manuela Neuman
Manuela Neuman
Lawrence Serfaty
Lawrence Serfaty
Anca Trifan
Anca Trifan
Simona Valean
Simona Valean
Laura Iliescu
Laura Iliescu
Victor Zota
Victor Zota